Coenzyme Q10 dose-escalation study in hemodialysis patients: Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation

Catherine K. Yeung, Frederic T. Billings, Adam J. Claessens, Baback Roshanravan, Lori Linke, Mary B. Sundell, Suhail Ahmad, Baohai Shao, Danny D. Shen, T. Alp Ikizler, Jonathan Himmelfarb

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress. Methods: We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships. Results: Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study. Conclusions: CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis. Trial Registration: This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.

Original languageEnglish (US)
Article number183
JournalBMC Nephrology
Volume16
Issue number1
DOIs
StatePublished - Nov 3 2015
Externally publishedYes

Fingerprint

coenzyme Q10
Patient Safety
Renal Dialysis
Dialysis
Oxidative Stress
Transplantation
F2-Isoprostanes
Oxidative Phosphorylation

Keywords

  • Clinical study
  • Coenzyme Q
  • Hemodialysis
  • Kidney disease
  • Oxidative stress

ASJC Scopus subject areas

  • Nephrology

Cite this

Coenzyme Q10 dose-escalation study in hemodialysis patients : Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation. / Yeung, Catherine K.; Billings, Frederic T.; Claessens, Adam J.; Roshanravan, Baback; Linke, Lori; Sundell, Mary B.; Ahmad, Suhail; Shao, Baohai; Shen, Danny D.; Ikizler, T. Alp; Himmelfarb, Jonathan.

In: BMC Nephrology, Vol. 16, No. 1, 183, 03.11.2015.

Research output: Contribution to journalArticle

Yeung, CK, Billings, FT, Claessens, AJ, Roshanravan, B, Linke, L, Sundell, MB, Ahmad, S, Shao, B, Shen, DD, Ikizler, TA & Himmelfarb, J 2015, 'Coenzyme Q10 dose-escalation study in hemodialysis patients: Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation', BMC Nephrology, vol. 16, no. 1, 183. https://doi.org/10.1186/s12882-015-0178-2
Yeung, Catherine K. ; Billings, Frederic T. ; Claessens, Adam J. ; Roshanravan, Baback ; Linke, Lori ; Sundell, Mary B. ; Ahmad, Suhail ; Shao, Baohai ; Shen, Danny D. ; Ikizler, T. Alp ; Himmelfarb, Jonathan. / Coenzyme Q10 dose-escalation study in hemodialysis patients : Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation. In: BMC Nephrology. 2015 ; Vol. 16, No. 1.
@article{4b1221288fb542978df83375a4bc6669,
title = "Coenzyme Q10 dose-escalation study in hemodialysis patients: Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation",
abstract = "Background: Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress. Methods: We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships. Results: Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study. Conclusions: CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis. Trial Registration: This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.",
keywords = "Clinical study, Coenzyme Q, Hemodialysis, Kidney disease, Oxidative stress",
author = "Yeung, {Catherine K.} and Billings, {Frederic T.} and Claessens, {Adam J.} and Baback Roshanravan and Lori Linke and Sundell, {Mary B.} and Suhail Ahmad and Baohai Shao and Shen, {Danny D.} and Ikizler, {T. Alp} and Jonathan Himmelfarb",
year = "2015",
month = "11",
day = "3",
doi = "10.1186/s12882-015-0178-2",
language = "English (US)",
volume = "16",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Coenzyme Q10 dose-escalation study in hemodialysis patients

T2 - Safety, tolerability, and effect on oxidative stress Dialysis and Transplantation

AU - Yeung, Catherine K.

AU - Billings, Frederic T.

AU - Claessens, Adam J.

AU - Roshanravan, Baback

AU - Linke, Lori

AU - Sundell, Mary B.

AU - Ahmad, Suhail

AU - Shao, Baohai

AU - Shen, Danny D.

AU - Ikizler, T. Alp

AU - Himmelfarb, Jonathan

PY - 2015/11/3

Y1 - 2015/11/3

N2 - Background: Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress. Methods: We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships. Results: Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study. Conclusions: CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis. Trial Registration: This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.

AB - Background: Coenzyme Q10 (CoQ10) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ10 in chronic hemodialysis patients, a population subject to increased oxidative stress. Methods: We performed a dose escalation study to test the hypothesis that CoQ10 therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of F2-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ10 concentrations were measured to determine dose, concentration and response relationships. Results: Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ10 levels increased in a linear fashion from 704 ± 286 ng/mL at baseline to 4033 ± 1637 ng/mL, and plasma isofuran concentrations decreased from 141 ± 67.5 pg/mL at baseline to 72.2 ± 37.5 pg/mL at the completion of the study (P = 0.003 vs. baseline and P < 0.001 for the effect of dose escalation on isofurans). Plasma F2-isoprostane concentrations did not change during the study. Conclusions: CoQ10 supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ10 supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ10 supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis. Trial Registration: This clinical trial was registered on clinicaltrials.gov [ NCT00908297 ] on May 21, 2009.

KW - Clinical study

KW - Coenzyme Q

KW - Hemodialysis

KW - Kidney disease

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84959196127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959196127&partnerID=8YFLogxK

U2 - 10.1186/s12882-015-0178-2

DO - 10.1186/s12882-015-0178-2

M3 - Article

C2 - 26531095

AN - SCOPUS:84959196127

VL - 16

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 183

ER -